Sunshine Guojian Pharmaceutical (Shanghai) Future Growth
Future criteria checks 1/6
Sunshine Guojian Pharmaceutical (Shanghai)'s earnings are forecast to decline at 11.7% per annum while its annual revenue is expected to grow at 17.8% per year. EPS is expected to decline by 11.6% per annum. Return on equity is forecast to be 5.7% in 3 years.
Key information
-11.7%
Earnings growth rate
-11.6%
EPS growth rate
| Biotechs earnings growth | 45.2% |
| Revenue growth rate | 17.8% |
| Future return on equity | 5.7% |
| Analyst coverage | Low |
| Last updated | 30 Oct 2024 |
Recent future growth updates
Recent updates
Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Oct 29
There's Reason For Concern Over Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd's (SHSE:688336) Massive 30% Price Jump
Oct 01What Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd's (SHSE:688336) P/E Is Not Telling You
Jul 25Is Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) A Risky Investment?
Jun 20If EPS Growth Is Important To You, Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) Presents An Opportunity
May 24We Think That There Are Issues Underlying Sunshine Guojian Pharmaceutical (Shanghai)'s (SHSE:688336) Earnings
Mar 31Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHSE:688336) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Mar 04Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,596 | 356 | 247 | 329 | 4 |
| 12/31/2025 | 1,340 | 305 | 213 | 332 | 4 |
| 12/31/2024 | 1,247 | 534 | 93 | 472 | 4 |
| 9/30/2024 | 1,223 | 364 | 128 | 306 | N/A |
| 6/30/2024 | 1,133 | 329 | 229 | 395 | N/A |
| 3/31/2024 | 1,074 | 352 | 296 | 461 | N/A |
| 12/31/2023 | 1,014 | 295 | 181 | 416 | N/A |
| 9/30/2023 | 1,029 | 212 | 31 | 386 | N/A |
| 6/30/2023 | 963 | 151 | -59 | 284 | N/A |
| 3/31/2023 | 872 | 82 | -98 | 208 | N/A |
| 12/31/2022 | 825 | 49 | 12 | 233 | N/A |
| 9/30/2022 | 828 | 14 | -132 | 45 | N/A |
| 6/30/2022 | 791 | -12 | -160 | 39 | N/A |
| 3/31/2022 | 934 | 50 | -330 | -80 | N/A |
| 12/31/2021 | 929 | 18 | -508 | -244 | N/A |
| 9/30/2021 | 697 | -155 | -450 | -205 | N/A |
| 6/30/2021 | 783 | -137 | -461 | -205 | N/A |
| 3/31/2021 | 757 | -148 | -352 | -124 | N/A |
| 12/31/2020 | 655 | -217 | -267 | -40 | N/A |
| 9/30/2020 | 1,009 | 117 | -2 | 227 | N/A |
| 6/30/2020 | 1,011 | 154 | 220 | 398 | N/A |
| 3/31/2020 | 1,155 | 194 | N/A | N/A | N/A |
| 12/31/2019 | 1,177 | 229 | 457 | 588 | N/A |
| 12/31/2018 | 1,142 | 370 | 271 | 361 | N/A |
| 12/31/2017 | 1,103 | 389 | N/A | 235 | N/A |
| 12/31/2015 | 877 | 211 | N/A | 336 | N/A |
| 12/31/2014 | 776 | 212 | N/A | 264 | N/A |
| 12/31/2013 | 728 | 295 | N/A | 276 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688336's earnings are forecast to decline over the next 3 years (-11.7% per year).
Earnings vs Market: 688336's earnings are forecast to decline over the next 3 years (-11.7% per year).
High Growth Earnings: 688336's earnings are forecast to decline over the next 3 years.
Revenue vs Market: 688336's revenue (17.8% per year) is forecast to grow faster than the CN market (13.8% per year).
High Growth Revenue: 688336's revenue (17.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688336's Return on Equity is forecast to be low in 3 years time (5.7%).